Although significant progress has been made in the treatment and management of patients with FL, several challenges remain, including the need to develop better prognostic models and markers for ...

Please provide your email address to receive an email when new articles are posted on . Low-dose aspirin significantly reduced risk for colorectal cancer recurrence among patients with mutations in ...

The FDA approved the PI3K-pathway inhibitor inavolisib (Itovebi) for use in combination with palbociclib (Ibrance) and fulvestrant to treat locally advanced, PIK3CA ...

In December 2025, Celcuity Inc. reported updated Phase 3 VIKTORIA-1 trial results at the San Antonio Breast Cancer Symposium, showing gedatolisib-based regimens improved progression-free survival and ...